Skip to main content
Find more clinical trials

Retinal Imaging for Mild Cognitive Impairment and Alzheimer's Disease

Start: July 2017
End: December 31, 2022
Enrollment: 1000

What Is This Study About?

Noninvasive retinal imaging may be able to identify biomarkers, or signs within the body, associated with mild cognitive impairment (MCI), Alzheimer's disease, and Parkinson's Disease (PD), or other neurodegenerative disease. In this study, researchers are investigating the optical coherence tomography angiography (OCTA) imaging technique as a potential screening tool. Participants will undergo noninvasive eye scans with OCTA. Researchers will use the scans to assess the structure and function of retinal blood vessels in people with these diseases  compared to those without.

Do I Qualify To Participate in This Study?

Minimum Age: 18 Years

Maximum Age: N/A

Must have:

  • Diagnosis of MCI, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and Huntington's disease.

Must NOT have:

  • Diagnosis of a dementia other than Alzheimer's
  • Diabetes
  • Evidence of glaucoma, macular degeneration, or other neurologic or age-related eye or vision condition that could impact results
  • Previous eye surgery, other than cataract surgery
  • Inability to cooperate with or complete testing

Note: If two eyes satisfy the inclusion criteria, both eyes will be included in the study. If one eye satisfies the inclusion criteria, the eye that qualifies will be included in the study.

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 
Study Contact
Dilraj Grewal, MD

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

North Carolina
Duke University Medical Center
Durham, NC 27705
Recruiting
Dilraj Grewal, MD

Who Sponsors This Study?

Lead: Duke University

Source: ClinicalTrials.gov ID: NCT03233646